A Man On Fire Fueled By A Mission To Find A Drug For Every Disease
Executive Summary
David Fajgenbaum has become a "man on fire," determined to repurpose as many generic drugs as possible for diseases without approved treatments. Fajgenbaum, whose efforts have been recognized by former President Bill Clinton, spoke with In Vivo about his own patient journey with a disease with no approved treatment and about the Every Cure Foundation, a non-profit he co-founded to fulfill his ambitions.
You may also be interested in...
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.
Fostering a Culture of Innovation, From Evolutionary To Revolutionary
Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.
Radical Honesty Is Part Of The Secret To Apellis's Success
On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.